ADRA1D (ADA1D_HUMAN), A Potential Drug Target and Biomarker for the Treatment of Parkinson's Disease

Target Name: ADRA1D

NCBI ID: G146

ADRA1D

ADRA1D (ADA1D_HUMAN), A Potential Drug Target and Biomarker for the Treatment of Parkinson's Disease

Introduction

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, bradykinesia, and postural instability. It affects an estimated 10 million people worldwide and is typically diagnosed in the late 30s or early 40s. While several FDA-approved drugs are available for the treatment of Parkinson's disease, there is still a need for new and more effective treatments.

ADRA1D (ADA1D_HUMAN) is a protein that is expressed in the brain and has been shown to play a role in the development and progression of Parkinson's disease. It is a potential drug target and biomarker that could be used to treat this debilitating disorder.

The Importance of ADRA1D in Parkinson's Disease

ADRA1D is a transmembrane protein that is expressed in the brain and is involved in the regulation of dopamine (neurotransmitter) levels. Dopamine is a neurotransmitter that plays a critical role in movement and cognition. Parkinson's disease is characterized by the loss of dopamine- producing neurons in the brain, leading to the observed symptoms of tremors, rigidity, bradykinesia, and postural instability.

ADRA1D has been shown to be involved in the development and progression of Parkinson's disease by promoting the production of dopamine-producing neurons, protecting dopamine-producing neurons from death, and modulating the levels of dopamine in the brain.

ADRA1D as a Potential Drug Target

The loss of dopamine-producing neurons in Parkinson's disease is thought to contribute to the development and progression of the disease. Therefore, targeting ADRA1D, a protein that is involved in the regulation of dopamine levels, could be a promising strategy for the treatment of Parkinson's disease.

One approach to targeting ADRA1D is to use small molecules, such as drugs that bind to ADRA1D and prevent it from functioning. This could involve using drugs that modulate the levels of dopamine in the brain, or drugs that interfere with the activity of ADRA1D.

In addition to small molecules, another approach to targeting ADRA1D could be to use antibodies that specifically bind to ADRA1D and prevent it from functioning. This approach has the advantage of being highly specific and can be used to target ADRA1D without affecting other proteins in the brain.

The Potential of ADRA1D as a Biomarker

ADRA1D has also been shown to be a potential biomarker for the diagnosis of Parkinson's disease. The levels of ADRA1D have been shown to be reduced in the brains of people with Parkinson's disease compared to healthy controls. This suggests that ADRA1D may be a useful biomarker for the diagnosis of Parkinson's disease.

In addition to its potential as a drug target, ADRA1D may also be a useful biomarker for the diagnosis of Parkinson's disease. The levels of ADRA1D have been shown to be reduced in the brains of people with Parkinson's disease compared to healthy controls. This suggests that ADRA1D may be a useful biomarker for the diagnosis of Parkinson's disease, particularly in cases where dopamine levels are not available for measurement.

Conclusion

ADRA1D (ADA1D_HUMAN) is a protein that is expressed in the brain and has been shown to play a role in the development and progression of Parkinson's disease. It is a potential drug target and biomarker that could be used to treat this debilitating disorder. Further research is needed to fully understand the role of ADRA1D in Parkinson's disease and to develop effective treatments.

Protein Name: Adrenoceptor Alpha 1D

Functions: This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium

The "ADRA1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADRA1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets